Checkpoint Surgical

Checkpoint Surgical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $26M

Overview

Checkpoint Surgical is a leader in the peripheral nerve care market, empowering surgeons with innovative tools for nerve protection, identification, and repair. The company's mission is to improve patient and physician quality of life through advancements in nerve surgery, supported by a comprehensive portfolio of stimulators, biomaterials, and instruments. It actively engages in surgeon education and clinical research, including a pivotal trial for its investigational nerve regeneration system, Regen10®. Strategically, Checkpoint is expanding its product offerings across the continuum of intraoperative nerve care.

Peripheral Nerve InjurySurgical NeurologyNerve RepairTendon RepairPost-Amputation PainSpasticity

Technology Platform

Integrated platform for intraoperative nerve care featuring proprietary biphasic waveform nerve stimulators, dehydrated placental membrane allograft biomaterials, and specialized nerve-specific surgical instruments.

Funding History

3
Total raised:$26M
Series B$15M
Series A$8.5M
Seed$2.5M

Opportunities

Significant growth opportunities exist in expanding into new surgical specialties (orthopedics, plastics, neurosurgery), supporting emerging procedures like Targeted Muscle Reinnervation for pain, and commercializing the investigational Regen10® nerve regeneration system.
The integrated portfolio approach allows Checkpoint to address the full continuum of nerve care.

Risk Factors

Key risks include clinical trial failure or delay for Regen10®, intense competition from larger medical device companies, dependence on surgeon adoption of specific nerve repair techniques, and potential reimbursement challenges for new products.

Competitive Landscape

Checkpoint competes with companies like AxoGen and Integra LifeSciences in nerve repair, and various providers of intraoperative nerve stimulators. Its differentiation lies in its focused, integrated portfolio for nerve surgery, proprietary stimulation technology, and a strong commitment to surgeon education and community building, which fosters brand loyalty.